3D medical imaging transforms diagnostics and treatment, enhancing precision, patient education, and enabling AI-driven analysis and immersive experiences.
Human Body Imaging
Positron Emission Tomography (PET) is an imaging modality used in neurology and oncology and, in some cases, used in conjunction with magnetic resonance imaging (MRI). PET defines the radiotherapeutic target volume of a tumour or the extent of disease before surgically removing a tissue structure or organ from the human body.
PET also assists in establishing a prognostic value about the patients’ overall cancer outcome, regardless of therapy through molecular imaging. For example, the PET radiotracer, fluorine-18 labelled fluoroethyltyrosine (18F-FET), has been shown to predict the prognosis of improved target delineation to assess treatment response.
A recent study using 18F-FET-PET and T1 weighted image MRI was used to predict the treatment effectiveness following glioblastoma patients’ chemoradiation therapy. The radiotracer fluorodopa F-18 (fluoro-deoxyphenylalanine 18F-DOPA) provides additional clinical information that may be validated by histopathology. Another target for brain tumour imaging is the translocator protein (TSPO).
This protein is overexpressed in glioblastoma patients, and clinical investigations have shown a link to the neuro-inflammatory component by observing a TSPO PET signal. Positron Emission Tomography is also used to evaluate head and neck cancers such as nasopharyngeal carcinomas, squamous cell cancer and salivary tumours.
Furthermore, the hybrid PET and computed tomography (CT) scanner can provide insight into the status of nodal metastases of the tumour and tissue metabolism. PET/CT enables contouring for chemotherapy and radiotherapy in radiation treatment planning. Lung cancer occurs in 80-90% of non-small cell lung cancer (NSCLC) patients. PET imaging with 18F-FDG (fluorodeoxyglucose) is used for staging patients with NSCLC.
In another diagnostic investigation, PET/CT PSMA (prostate-specific membrane antigen) ligands labelled with gallium-68 or fluorine-18 is used in prostate cancer screening programmes because it provides an excellent target-to-background ratio, leading to a better detection rate. PSMA is highly specific for prostatic tumoral tissue.
You Are Here: Home » positron emission tomography
3D medical imaging transforms diagnostics and treatment, enhancing precision, patient education, and enabling AI-driven analysis and immersive experiences.
Large vessel vasculitis and polymyalgia rheumatica are both inflammatory rheumatic diseases that can result in serious illness if not diagnosed.
Positrons, alpha particles, beta particles, and electron capture contribute to nuclear medicine, diagnostics, and diverse scientific applications.
Advanced medical imaging technologies transformed liver disease detection, diagnosis and management, enhancing diagnostic accuracy and personalized treatments.
Indium-111 oxyquinoline enables diverse cellular imaging, crucial for detecting infections, thrombosis, tumours, and advancing stem cell research.
Alzheimer's disease, an age-related neurodegenerative disorder, impacts brain structure and function, requiring advanced imaging techniques for improved understanding and diagnosis.
Gallium-68 DOTATATE, a radiopharmaceutical, targets somatostatin receptors, aiding neuroendocrine tumor detection through PET imaging, enhancing diagnostic accuracy and patient outcomes.
Fluorine-18 Flutemetamol, a radioactive tracer, for early detection of Alzheimer's disease through PET imaging, enhancing diagnostic accuracy.
Fluorine-18 Florbetaben is a radiotracer used in medical imaging to detect amyloid plaques in the brain.
Theranostics is a cutting-edge approach that integrates diagnosis and therapy, enabling personalised and precise disease management.
PET imaging is used in oncology, neurology and cardiology.
Evaluation of metastatic castrate-resistant prostate cancer using fluorine-18 choline PET-CT imaging.
PET/CT images are used for detecting, staging and monitoring various malignant tumours.
Neuroendocrine tumours include a spectrum of neoplasms characterized by histologic heterogeneity.